Kinomica, founded in 2016 and headquartered in the United Kingdom, is a notable player in the biopharma and biotechnology industries. It operates as a precision medicine research and diagnostics company with a strong niche in cell signalling. Known for its interdisciplinary approach, Kinomica leverages a unique phosphoproteomics platform that merges LC–MS/MS with cutting-edge proprietary bioinformatics to offer tailored R&D and diagnostic services.
Most recently, Kinomica secured a £3.90M Series A investment on 14 December 2020. This round attracted the interest and backing of investors like Longwall Ventures, Alderley Park Ventures, Puffin Point, BioCity Group, and the Business Growth Fund. The capital influx is poised to bolster Kinomica's promising platform, positioning the company for further growth in the lucrative precision medicine market.